register

News & Trends - MedTech & Diagnostics

Cutting-edge technology to bridge gap between cancer diagnosis and research

Health Industry Hub | August 10, 2023 |

MedTech & Diagnostics News: Northern Sydney Local Health District has ushered in a new era of medical imaging and research with the inauguration of an ultra-advanced total body PET scanner. The cutting-edge Siemens Quadra total-body PET/CT scanner, the second in Australia and one of only fifteen globally, has taken centre stage at the hospital, bidding farewell to its predecessor CT/PET scanner that diligently served the community for thirteen years.

With a history dating back to its grand opening in March 2010, the outgoing machinery, inaugurated by the former Prime Minister Kevin Rudd, conducted close to 50,000 scans during its tenure, predominantly catering to cancer patients. However, the torch has been passed to a marvel of technology that promises to redefine medical imaging as we know it.

The new Siemens Quadra total-body PET/CT scanner, a collaborative effort between Royal North Shore Hospital (RNSH) and the University of Sydney, stands poised to enhance patient care and propel Australia to the forefront of PET/CT research. Backed by a substantial $15 million national initiative, this project has the potential to reshape the landscape of medical diagnostics and therapeutic exploration.

Dr Paul Roach, Director of Nuclear Medicine at RNSH, has hailed the new scanner as a game-changer on multiple fronts. Not only will it dramatically reduce radiation exposure, with doses anticipated to be halved compared to current standards, but it will also operate at an accelerated pace, providing quicker and more accurate results.

“By harnessing the power of this advanced technology, we are embarking on a new era of medical imaging that promises safer and swifter diagnoses,” remarked Dr Roach.

In a bold departure from tradition, this innovative PET/CT scanner will serve a dual purpose, seamlessly bridging the gap between clinical research and patient care. Beyond its critical role in diagnosing cancer, the scanner will be used in conditions such as dementia, Parkinson’s disease, and perplexing infections, marking a pioneering step forward in the realm of diagnostic versatility.

“The new scanner is akin to capturing the entire essence of the body in a single frame, streamlining the diagnostic process while preserving patient safety. At least half the time the scanner will be used for our (hospital) patients and the other time it will be used by the university for clinical research,” enthused Dr Roach.

Supported by a robust partnership between the University of Sydney, the Federal Government’s National Imaging Facility, and Northern Sydney Local Health District, the acquisition of the Siemens Quadra is a testament to collaborative efforts driving medical innovation.

Reimagining healthcare across the entire patient journey: Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change in healthcare.

The content on Health Industry Hub is copyright protected and can only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.